|
Name |
Stigmasta-5,22-dien-3-ol acetate
|
Molecular Formula | C31H50O2 | |
IUPAC Name* |
[(8S,9S,10R,13R,14S,17R)-17-[(2R,5S)-5-ethyl-6-methylhept-3-en-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate
|
|
SMILES |
CC[C@H](C=C[C@@H](C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CCC(C4)OC(=O)C)C)C)C(C)C
|
|
InChI |
InChI=1S/C31H50O2/c1-8-23(20(2)3)10-9-21(4)27-13-14-28-26-12-11-24-19-25(33-22(5)32)15-17-30(24,6)29(26)16-18-31(27,28)7/h9-11,20-21,23,25-29H,8,12-19H2,1-7H3/t21-,23-,25?,26+,27-,28+,29+,30+,31-/m1/s1
|
|
InChIKey |
IZEUIYYDWBKERE-RWKSKRQGSA-N
|
|
Synonyms |
stigmasta-5,22-dien-3-ol acetate
|
|
CAS | NA | |
PubChem CID | 129885398 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 454.7 | ALogp: | 9.1 |
HBD: | 0 | HBA: | 2 |
Rotatable Bonds: | 7 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 26.3 | Aromatic Rings: | 4 |
Heavy Atoms: | 33 | QED Weighted: | 0.276 |
Caco-2 Permeability: | -4.538 | MDCK Permeability: | 0.00001130 |
Pgp-inhibitor: | 0.99 | Pgp-substrate: | 0.001 |
Human Intestinal Absorption (HIA): | 0.002 | 20% Bioavailability (F20%): | 0.983 |
30% Bioavailability (F30%): | 0.493 |
Blood-Brain-Barrier Penetration (BBB): | 0.058 | Plasma Protein Binding (PPB): | 93.57% |
Volume Distribution (VD): | 1.933 | Fu: | 1.36% |
CYP1A2-inhibitor: | 0.058 | CYP1A2-substrate: | 0.249 |
CYP2C19-inhibitor: | 0.146 | CYP2C19-substrate: | 0.882 |
CYP2C9-inhibitor: | 0.263 | CYP2C9-substrate: | 0.085 |
CYP2D6-inhibitor: | 0.723 | CYP2D6-substrate: | 0.526 |
CYP3A4-inhibitor: | 0.82 | CYP3A4-substrate: | 0.726 |
Clearance (CL): | 3.782 | Half-life (T1/2): | 0.044 |
hERG Blockers: | 0.083 | Human Hepatotoxicity (H-HT): | 0.078 |
Drug-inuced Liver Injury (DILI): | 0.847 | AMES Toxicity: | 0.005 |
Rat Oral Acute Toxicity: | 0.007 | Maximum Recommended Daily Dose: | 0.085 |
Skin Sensitization: | 0.942 | Carcinogencity: | 0.111 |
Eye Corrosion: | 0.072 | Eye Irritation: | 0.121 |
Respiratory Toxicity: | 0.385 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC001846 | 1.000 | D0Y7LD | 0.582 | ||||
ENC001545 | 0.794 | D0B4RU | 0.505 | ||||
ENC001647 | 0.750 | D06CNP | 0.438 | ||||
ENC001475 | 0.702 | D0K0EK | 0.389 | ||||
ENC001558 | 0.676 | D07BSQ | 0.384 | ||||
ENC004758 | 0.676 | D02CJX | 0.383 | ||||
ENC001889 | 0.659 | D0W5LS | 0.362 | ||||
ENC003458 | 0.657 | D09NNA | 0.358 | ||||
ENC002290 | 0.654 | D0G8OC | 0.357 | ||||
ENC005068 | 0.627 | D06XMU | 0.351 |